Thirty-two patients with aplastic anemia (AA) have been studied using the long-term bone marrow culture (LTBMC) system. Of these patients, 26 had been treated with immunosuppressive therapy including antilymphocyte globulin (ALG) with or without androgens or high-dose methyl prednisolone. The remaining six patients either required no treatment or were studied before therapy was begun. Thirty-one of 32 patients (96%) had defective hematopoiesis in LTBMC with little or no evidence for the generation of primitive progenitor cells. The only exception was a patient with spontaneous recovery of aplasia in whom the defect was less marked. Crossover LTBMC experiments were performed in 23 cases by inoculating (1) patient marrow hematopoietic cells that had been depleted of adherent cells onto preformed, irradiated, normal stromas to assess ANY PATHOGENETIC mechanisms have been pro-
M posed to account for the bone marrow failure in aplastic anemia (AA). These include a primary stem cell deficiency or defect, a secondary stem cell defect due to abnormal regulation by cellular or humoral factors, or a deficiency in the stromal cell "microen~ironment."~~~ Studies from syngeneic bone marrow transplantation (BMT) for AA have demonstrated that a stem cell defect may account for approximately 50% of cases because infusion of syngeneic marrow alone without prior immunosuppressive conditioning treatment will result in sustained engraftment in these patients.' Evidence postulated for hematopoiesis being due to a stromal cell-mediated defect comes from studies using two genetically anemic strains of mice (Sl/Sld and W / W ) , which have shown that the stromal defect in Sl/Sld mice and the stem cell defect characterizing W/W' mice are crosscorrecting in vitro and in vivo. 6 However, there have only been a few clinical cases documenting stromal defects in AA7 and congenital hypoplastic anemia.-' Evidence has also been found for immune suppression of hematopoiesis by activated T-suppressor cells in some cases of AA,438 and recently a deficiency of interleukin-1 has been reported in 10 of 17 patients in one series. ' Investigations to examine these pathogenetic mechanisms have largely involved the use of short-term colony assays. The long-term bone marrow culture system (LTBMC), as first described by Dexter et all0 with subsequent modification by Gartner and Kaplan," represents the most physiologic in vitro system to study the interaction of hematopoietic cells with stroma, and thus provides an ideal system for investigating these pathogenetic mechanisms in AA. However, very few studies of AA in LTBMC have been reported. A reduction or absence of neutrophil/macrophage progenitor cell (colony-forming unit [CFUI-GM) production in LTBMC in patients with AA has been documented by three g r o~p s , l~-'~ and Hotta et a17 demonstrated abnormal stromal function in a third of patients studied when stromal cells from patients with AA were irradiated and then recharged with normal bone marrow.
We have studied 32 cases of AA in LTBMC, including crossover experiments in 23, to further elucidate the pathogenesis of this disorder in humans.
PATIENTS AND METHODS

Patients
A total of 32 patients with AA were included in the study ( Table   1) . At diagnosis, 6 had severe AA and 26 nonsevere AA as defined by Camitta et al." The median duration of aplasia was 28 months (range 1 to 360). Of 32 patients, 26 had received prior immunosuppressive therapy for their disease. Six were untreated (apart from red blood cell and platelet transfusions in two patients), 3 because of mild disease (patients 27, 30, and 31). 1 because of spontaneous recovery of the aplasia (patient 28), and 2 patients were studied before commencement of specific treatment (patients 28 and 32). Immunosuppressive therapy included one or two courses of antilymphocyte globulin (ALG, horse and antithymocyte globulin, rabbit, Merieux, England). One patient received three courses of ALG. Details of the regimen and method of administration are as previously reported.I6 Oxymetholone was given to 18 of 23 patients who received ALG. At the time of study most of these patients were receiving a small reducing dose of the drug. One patient had received prednisolone with danazol, and one received folic acid on account of hemolysis caused by paroxysmal nocturnal hemoglobinuria (PNH). Patient 9 had had a splenectomy for resistant aplasia and three patients had had and/or were receiving cyclosporine. Six patients were still transfusion dependent and the remaining patients (20 of n   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31 NS  S  NS  NS  NS  NS  NS  NS  NS  NS  NS  NS  NS  NS  NS   S   S  NS  NS  NS  NS   S   NS  NS  NS  S  NS  NS  NS  NS  NS  NS   NS  NS  NS  NS  NS  NS  NS  NS  NS  NS  NS  NS  NS  NS  NS  NS   S   NS  NS  NS  NS  NS  NS  NS  NS  NS  NS  NS  NS  NS  NS 153  27  29  31  118  49  60  11  46  93  26  57  154  13  6  108  30  132  40  170  91  124  57  31  177  42  69  129  14  74  76 
Bone Marrow Samples
Adult patients were sedated with intravenous midazolam and approximately 20 to 40 mL of bone marrow aspirated in 2-to 3-mL aliquots from the posterior iliac crest from several sites. Two children were included in this study, and the bone marrow was aspirated under general anesthetic. Marrow was collected into media consisting of 15% fetal calf serum (FCS) in Iscoves medium (GIBCO, Grand Island, NY) or RPMI 1640 (GIBCO) and preservative-free heparin. Bone marrow samples were also obtained from normal donors of bone marrow transplant recipients during the bone marrow harvest, after informed written consent, and from ribs excised at the time of cardiothoracic surgery. Informed written consent was obtained from all patients according to the practice of the Local Hospital Ethical Committees.
All samples were processed within 24 hours and cell viability assessed by trypan blue dye exclusion. Marrow aspirates were diluted further in Iscove's medium and an aliquot separated on Ficoll-Hypaque (1.077 g/m', Flow Laboratories, Irvine, Scotland) to obtain the light density mononuclear fraction for mixed lineage colony-forming cells (CFU-MIX) and early erythroid burst-forming unit (BFU-E) assays. For CFU-GM and fibroblast colony (CFU-F) assays, and LTBMC, marrow cells were obtained from the supernate after sedimentation in 0.1% methyl cellulose.
Colony Assays
Analysis of CFU-GM was performed by plating lo5 cells in Iscove's medium supplemented with 15% preselected FCS and 20% 5637 conditioned medium in 0.3% agar. Cultures were incubated at 37OC in a humidified atmosphere of 5% CO, in air and colonies scored in triplicate on days 9 to 11 using a dissecting microscope. Colonies were defined as aggregates of 50 cells or more. Neutrophil/ macrophage morphology was confirmed on cytospin preparations of isolated colonies.
For analysis of CFU-Mix and BFU-E, the light-density mononuclear marrow cells obtained after separation with Ficoll-Hypaque were washed twice in Iscove's medium, and lo5 cells/mL were plated in 1.3% methyl cellulose in Iscoves medium using 2 U of recombinant human erythropoietin (Terry Fox Laboratories, Vancouver, Canada), 30% FCS, 10% 5637 conditioned medium, and 10% bovine serum albumin with bicarbonate. Cultures were incubated at 37OC in a humidified atmosphere gassed with 5% CO, and 5% 0, in air. Mixed colonies (CFU-Mix) were identified by the presence of both granulocytic and erythroid elements in single colonies. Erythroid colonies (BFU-E) consisting of three or more clusters were recognized by their characteristic brick red appearance. Most assays were set up in duplicate and both CFU-Mix and BFU-E scored on day 14.
Fibroblast colonies (CFU-F) were cultured by plating 5 x IO5 marrow cells in triplicate, separated by sedimentation in 1% methyl cellulose, into 25 cm2 Falcon tissue culture flasks in 5 mL Iscove's medium containing 15% FCS. The flasks were gassed with 5% CO, in air and incubated at 37OC. The medium was discarded and replaced with fresh medium on day 3 or 4 and the cultures were ended on day 11. The flasks were then washed twice with phosphatebuffered saline, and the colonies fixed with methanol and stained with 1% crystal violet. Colonies containing 50 cells or more were scored as CFU-F using a dissecting microscope.
Long-Term Bone Marrow Cultures
Standard LTBMC Method
Bone marrow cells that had been separated by sedimentation in 0.1% methyl cellulose were incubated at a concentration of 1.3 to 2.0 x 106/mL (mean value 1.7 x 106/mL for normal controls and 1.9 x 106/mL for patients with AA) in 10 mL Iscove's medium containing 10% preselected FCS, 10% preselected horse serum, and 5 x lo7 mol/L hydrocortisone in 25-cm2 Falcon tissue culture flasks. Flasks were gassed with 5% CO, in air, incubated at 33"C, and fed weekly by removing half the medium and replacing it with an equal volume of fresh medium. Each week the flasks were examined using an inverted microscope. Stromal layer formation was recorded and hematopoietic activity assessed by estimating visually the number of hematopoietic foci at <lo%, 25%, 50%, 75%, or 100% of normal controls. The harvested cells from the supernatant (nonadherent layer) were counted and assayed for CFU-GM weekly." After 6 weeks, stromal cell layers from six patients (patients 6, 10, 12, 16, 19, and 26) were detached by incubation in 0.25% trypsin for 10 minutes at 37OC. The detached cells were washed twice in 20% FCS in PBS, and the cells counted and assayed for CFU-GM in agar.
Crossover Experiments
Crossover experiments were performed by inoculating either patient or normal marrow cells (that had been adherent cell depleted to remove cells with the ability to contribute to stroma formation) onto patient or normal preformed irradiated stroma. Stromas were irradiated beforehand to eliminate hematopoietic cells present in the stromal layers. Confluent marrow stromal layers, precultured for 3 to 6 weeks in standard LTBMC conditions, were irradiated with 15 Gy using a cesium 137 source (Gammacell). All the supernatant was then removed and the culture recharged at 3 to 6 weeks with 5 x 105/mL adherent cell-depleted bone marrow cells in 10 mL of fresh culture medium. Thereafter, cultures were fed and maintained weekly as described above.
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Adherent Cell Depletion
For adherent cell depletion of bone marrow cells, the cells were incubated in 25-cm2 Falcon tissue culture flasks at a concentration of 1 to 2 x 106/mL in 5 mL 20% FCS in Iscove's medium. Flasks were gassed with 5% CO, in air and incubated at 37OC overnight. The following day two further incubations of these cells were performed for 1 hour each at 37OC in new flasks. The nonadherent cells were then collected and 5 x IO6 cells placed onto irradiated preformed stroma. To monitor the efficiency of adherent cell depletion, CFU-F assays were performed on the adherent cell-free fraction and compared with CFU-F assays before depletion. In addition, in nine of the crossover experiments 5 x lo6 adherent cell-depleted normal marrow cells were grown in LTBMC to look for residual stromal formation by weekly examination of the flask surface, monitoring of cell count, and CFU-GM activity in the supernatant. 
Statistical Analyses
Before analysis, the cell count data were subjected to a logarithmic transformation of the form Y' = In (Y + 1). Means, standard deviations, and confidence intervals were calculated using the transformed data. The data for cell counts was normalized by the number of cells seeded, and the zero time point excluded from the analysis. Standard two-way analysis of variance was used to determine the significance of differences between groups of cultures, or single cultures versus a control group. (Two-way classification models in time and group were used and tests performed on the significance of the group and group x time interaction effect. Significance values quoted are for the group effect.) Student's t-test was used to assess the standard error of the difference between two means in analysis of colony assay data, and regression analyses performed to look for correlation between two sets of observations.
RESULTS
Colony Assays
Results of clonal cultures of bone marrow for patients with AA are shown in Table 2 . Separate analyses were performed on cultures from treated and untreated patients. Patients with treated AA had significantly lower CFU-GM, CFUMix, and BFU-E compared with normal controls. Patients who were untreated had significantly lower CFU-GM com- 
CFU-mix (per lo5 cells) pared with the treated group, and although there was no obvious difference in the incidence of CFU-Mix and BFU-E, the number of patients studied was small. Although the mean values for colony assays in this series of patients were significantly reduced, there was a wide range of values with a proportion of patients exhibiting values within the normal range (38% of patients had normal numbers of BFU-E and 60% normal CFU-GM). For all patients the number of progenitors in the marrow did not reflect the severity of the aplasia, in that there was no difference in the number of CFU-GM, BFU-E, or CFU-Mix between those patients with normocellular marrow and those with reduced cellularity, and there was no correlation between marrow CFU-GM and peripheral blood neutrophil count (all regression coefficient values ranged from 0 to 0.15). Numbers of fibroblast colonies (CFU-F) were significantly increased in patients with treated AA compared with normal (P = .030), despite wide ranges of values in both AA and normals with considerable overlap between the two groups. Because the mean age of the normal controls (24 f 2.9 years) was significantly less than that of patients with AA (35.8 * 2.7 years, P < .01) a separate analysis on incidence of CFU-F was performed using age-matched controls. A similar difference in incidence of fibroblast colonies was seen between normals and patients with AA (23.2 f 5.11 and 53.0 f 1 1 .O CFU-F per 5 x lo5 cells, respectively, P = .027).
The increased CFU-F values in AA did not represent a relative increase due to bone marrow hypocellularity, but did represent an absolute increase because there was no correlation between CFU-F values and marrow cellularity (r = 0).
Long-Term Bone Marrow Culture Studies
Stroma Formation
All patients with AA (n = 32) were studied in LTBMC and results compared with 20 normal controls. The majority of patients and controls formed a confluent stroma, defined as 75% of flask surface covered by stromal cells within 3 to 5 weeks (Table 3) . Five patients who did not form a confluent stroma, produced between 50% and 60% coverage of the LTBMC flasks. Furthermore, two controls and five patients produced an "early" stroma defined as greater than 75% stroma by week 2 of culture. There was no difference in the mean time to confluence between patients and controls.
Morphologic differences between AA and normal stroma were documented. Differences included reduced number (less than 10% of normal) and shorter survival of hematopoietic foci in all individuals studied, except for patient 28, with 50% hematopoietic foci, late or absent fat cells in six patients
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From (late appearance defined by absence of fat cells until week 5), and early appearance of fat cells (present by week 2) in four patients. Of the five patients (patients 3, 7, 12, 17, and 29) who grew an early stroma, four had high levels of CFU-F with a mean of 81 colonies/5 x lo5 cells (CFU-F assay was not performed in the fifth patient), and two had early appearance of fat cells. Patient 6, who had trisomy 6, developed a phenotypically aberrant stroma: the cells were disorganized with fibroblasts layed down in all directions, some appearing more swollen than spindle shaped, giving a transformed appearance to the stroma.
Analysis of Hematopoiesis of Bone Marrow in LTBMC
In normal controls there was an early rapid decrease in cell numbers and CFU-GM in the nonadherent layer over the first 4 weeks of culture, followed by a plateau phase and/or small increase in both parameters over the next 4 to 5 weeks, and then a later decrease (Fig 1A and B) . In contrast, in 3 1 of 32 patients with AA, whether treated (Fig 1A and B) or untreated (Fig 2) (except for patient 28-see below), both total nucleated cells and CFU-GM per flask decreased rapidly to zero (within 4 weeks for CFU-GM and 7 to 8 weeks for total cells counted). No plateau phase was seen, indicating a lack of regenerative capacity of the hematopoietic cells in LTBMC even in those patients who clinically were complete responders with a normocellular bone marrow and normal incidence of marrow CFU-GM. A marked defect in hematopoiesis also was seen in the adherent layer in six patients evaluated at week 5 or 6, with values of less than 5 CFU-GM per flask recorded for all patients. This contrasts with a mean value of 1,307 CFU-GM per flask (range 152 to 4,680) for normal controls a t week 6 (L. Coutinho, personal communication, 1989). Of particular interest was patient 28, whose aplasia had recovered spontaneously after suspected non-A non-B hepatitis. In LTBMC a pattern of CFU-GM production was seen that was intermediate between normal controls and the other patients. Apart from this one case, cessation of CFU-GM production in the supernatant of LTBMC occurred by week 5 in all experiments, confirming a marked defect in hematopoiesis.
Crossover Experiments in LTBMC
To ascertain whether the defect of hematopoiesis defined in LTBMC in patients with AA was due to a hematopoietic or a stromal defect, crossover experiments were performed (see Crossover Experiments). For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Weeks i n Culture Growth of aplastic anemia hematopoietic cells on normal stroma. Adherent cell-depleted bone marrow cells from patients with AA were inoculated onto normal preformed irradiated stromas. All experiments were compared with results of five separate experiments obtained by inoculating adherent cell-depleted normal marrow cells onto different normal preformed irradiated stromas. The pattern of CFU-GM production in the nonadherent layer in this system differed from that obtained by growing unmanipulated normal bone marrow (Fig 3) in LTBMC in that hematopoiesis was maintained for a shorter period of time: CFU-GM could be detected for a mean of only 6.8 weeks (range 5 to 9 weeks) (Fig 3) compared with 12.1 weeks (range 8 to 14 weeks) for normal bone marrow grown in standard LTBMC. In comparison with the growth of normal marrow cells on normal stroma (n = 5 ) , hematopoietic cells from patients with treated AA (n = 17, patient 6 was studied on two occasions) demonstrated a defect in CFU-GM production when grown on normal stroma (Fig 3 and Table 4 ). CFU-GM numbers decreased rapidly to zero by week 4 or 5. Separate analyses comparing results from each patient with the group of normal controls demonstrated that every patient exhibited a highly significant defect in hematopoiesis when his or her hematopoietic cells were grown on normal stromas. First, CFU-GM were detected in the nonadherent layer for a shorter period of time, and second, significantly lower numbers of CFU-GM were present in the supernatant of LT-BMC ( Table 4 ). The severity of this hematopoietic defect did not correlate with either the duration or severity of aplasia in these patients.
In addition, three patients who had not received any prior treatment for their aplasia were studied. Patients 27 and 32
showed an identical response to the group of treated patients.
Patient 28, who had spontaneous recovery of aplasia before study, showed a pattern of CFU-GM growth on normal stroma intermediate between the treated group and normal controls ( Table 4) .
Growth of normal hematopoietic cells on stroma from patients with aplastic anemia. The normal adherent celldepleted control bone marrow cells that were inoculated onto normal stromas contained 3,196 + 725 (range 1,467 to 5,823) CFU-GM. All patients' stromas were inoculated with values of CFU-GM that fell within this normal range (mean 2,620, range 1,550 to 3,833). When comparing the group as a whole with the group of normal controls, for patients with AA there was no significant difference in the ability of the stroma to support normal hematopoiesis (P = .OS) (Fig 3) .
However, separate analysis comparing each patient's culture individually with the group of normal controls ( Table 4) Normal c e l l s showed that 1 AA stroma of 12 studied supported significantly reduced numbers of normal CFU-GM (P = .038), although numbers of CFU-GM were detected for a similar period of time. All other AA stromas functioned normally as assessed by their ability to support normal hematopoietic cells. However, there was more variability in stromal function among the patients compared with their stem cell function, with some patients exhibiting somewhat inferior stromal function compared with others, although still within normal limits. Furthermore, patient 6 was studied on two separate occasions, with some variability (within normal limits) seen in stromal function. Patients 27,28, and 29, who had received no prior treatment of their aplasia, were also studied, and in all cases their stromal function was normal in terms of both the duration of time and weekly numbers of CFU-GM assayed in LTBMC. The mean cell recovery from adherent cell depletion using normal marrow and AA marrow was 51 2.58% and 53.6 rtr 3.2%, enrichment of CFU-GM was 1.46-fold 0.12% and 1.34-fold rtr 0.36%, and loss of CFU-F 94.6 2.1% and 96 f 1.7%, respectively. In addition, as already described, in nine cases using normal bone marrow the adherent cell-depleted cells were put into LTBMC to see if any remaining adherent cells could give rise to areas of stroma formation. Table 5 shows that the greatest area of stroma formed by adherent cell-
Results of adherent cell depletions.
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The presence of areas of stroma formation appeared to be related to the efficiency of removal of CFU-F by adherent cell depletion (Table 5 ). Nevertheless, in no example was there sufficient stroma formation to be able to support the proliferation of hematopoietic cells when grown in LTBMC on their own as described previously. Thus, in the experiments performed where adherent cell-depleted hematopoietic cells were cocultured with a preformed stromal cell layer, the supportive microenvironment is probably a reflection of the preformed stromal cell layer; the contribution of donorderived stroma is likely to be insignificant.
DISCUSSION
Long-term bone marrow culture represents the most physiologic system for assessing growth of bone marrow cells in vitro." Proliferation and differentiation of stem cells are dependent on the intimate contact between the hematopoietic cells and a confluent stroma.20 Production of CFU-GM in the stroma (adherent layer) provides a better assessment of hematopoiesis compared with sampling CFU-GM shed into the supernatant (nonadherent layer). However, in this study we have primarily assessed hematopoiesis by counting CFU-GM in the nonadherent layer because of the difficulty in obtaining sufficient bone marrow from these patients to quantitate adherent layer hematopoiesis weekly. In keeping with the results of Juneja et the majority of patients with AA were able to form a confluent stroma in LTBMC. However, in all cases this was associated with a marked defect of hematopoiesis in LTBMC in all patients regardless of the degree of response to treatment or even whether or not they had been treated. The exception was a patient with post hepatitic AA who spontaneously recovered, and in whom the defect seen in LTBMC was intermediate between the pattern of normal controls and all other patients with AA studied. Compared with normal bone marrow (when sustained hematopoiesis can be demonstrated in LTBMC), these results in AA indicate little or no regenerative capacity of the hematopoietic cells. This implies a defect a t the stem cell level or in the capacity of marrow stromal cells to support hematopoiesis and further argues that there must be a compensatory increased downstream expression of more mature hematopoietic cells to maintain a normal or near normal peripheral blood count in patients who have responded to therapy. Therefore, in contrast to the basic hematologic parameters described and to the colony assays, LTBMC appears to be a sensitive method for detecting residual damage to bone marrow cells after treatment and subsequent recovery.
To distinguish between defects in the hematopoietic cells versus defects in the stromal cell environment, we performed crossover experiments. In this context it should be noted that Laver demonstrated the ability of normal LTBMC stromas irradiated with 15 Gy to support the growth of autologous bone marrow cells for 6 weeks." Also, Bruhl showed, using a microculture version of the LTBMC system, that irradiated normal stromas can support normal allogeneic hematopoietic cells for at least 8 weeks, and that irradiation doses up to 30 Gy do not interfere with stromal function.22 Furthermore, it has been shown that marrow cells from an HLA-mismatched source grow apparently normally on irradiated stromas without the problem of graft rejection or a graft-versus-host reaction, probably due to a relative deficiency of immunoreactive T cells23 and the use of hydrocortisone added routinely to LTBMC. Using LTBMC crossover experiments we demonstrated a defect in the regenerative capacity of the hematopoietic cells in all patients whether treated or untreated, shown by defective growth of AA hematopoietic cells on normal stroma. This defect was reflected in both the number of CFU-GM assayed weekly in the nonadherent layer and in a reduced period of time for detecting CFU-GM. From these experiments, the nature of the defect (presumably in the stem cell population) was not investigated, and further studies are required.
Functionally abnormal fibroblasts have been demonstrated in some patients with AA. J~n e j a~~ showed defective production of granulocyte-macrophage colony-stimulating factor (GM-CSF) by marrow fibroblasts in AA when grown in the absence of hydrocortisone. In contrast, Gordon and Gordon-Smith showed that although fibroblasts from some patients with AA had reduced colony-stimulating factorenhancing activity,25 their ability to stimulate growth of CFU-GM from marrow cells inoculated onto confluent fibroblast monolayers was either normal or supernormal.26 The system we have used to study stroma assesses the functional capacity of the stroma as an integral unit of many cell types rather than looking at the properties of isolated cellular components such as the fibroblasts, thus representing a more physiological in vitro system. In our study, apart from one patient, stromal function was normal as assessed by the ability of the stromal cells to support the growth of normal hematopoietic marrow cells in LTBMC, and thus to correct their growth defect in LTBMC. This low incidence of stromal defects may reflect the ability of the stroma to compensate or correct for any isolated abnormality of a certain cell type that might exist and thereby allow the stroma to support the growth of normal hematopoietic progenitors. The importance of performing crossover experiments to assess stromal and hematopoietic cell function is shown by patient 2, where stroma functioned normally in the crossover experiment despite forming a stroma in standard LTBMC that was not completely confluent. Furthermore, the stroma of patient 6, who had trisomy 6 and whose stroma appeared morphologically abnormal, functioned normally in its ability to support normal hematopoiesis. In contrast, Hotta et a1' demonstrated a stromal defect in three of nine For personal use only. on September 24, 2017. by guest www.bloodjournal.org From patients with AA by growing normal marrow cells on aplastic stroma. Most of their patients had severe AA of short duration. In Hotta's study, the possible existence of concurrent hematopoietic cell defects (ie, AA hematopoietic cells on normal stroma) was not examined. In contrast, in this study, in which most patients had long-standing nonsevere AA, we demonstrated a combined hematopoietic cell and stromal defect in only 1 of 11 patients studied on crossover experiments, although this patient was studied in LTBMC only on one occasion. Repeat studies at a later date should be performed to verify this abnormality of stromal function. This patient had responded to ALG and oxymethalone. She had long-standing ulcerative colitis treated with salazopyrine that remains quiescent clinically and required no treatment for 10 years before the onset of the aplasia. We therefore conclude from this study that residual stromal defects as assessed by LTBMC in AA after ALG treatment are not common. Furthermore, no indications of a stromal defect were found in the small number of patients who had not received any treatment for their aplasia.
It has long been recognized that AA is associated with a risk of developing PNH and acute myeloid leukemia (AML),27 although the latter risk was thought to be small. With the introduction of ALG and allogeneic BMT over the last 10 to 15 years as specific treatment for AA, patients now survive long-term. For those patients treated with allogeneic BMT, long-term survival figures of 70% to 80% are now consistently rep~rted.~'.~' Results of ALG therapy are more variable, with responses ranging from 35% to 70%.'6*32-34 It is now apparent that long-term survival after ALG therapy is associated with the later development of clonal disease, whereas long-term survival after BMT is not. Two separate studies have shown an increasing risk exceeding 50% of developing MDS, PNH, or AML 10 to 12 years after "successful" treatment with ALG.35*36 Late deaths have been reported from these complications. Furthermore, Appelbaum has reported that a small proportion of patients (4%) with otherwise typical AA at diagnosis have a clonal cytogenetic marker, without any hematologic evidence of MDS or le~kemia.~' Five of the patients with AA that we studied had a clonal chromosome marker. Of these, four were studied in LTBMC crossover experiments and all were shown to have stem cell defects with normal functioning stroma in LTBMC. To date, four of the five patients have not shown any evidence of MDS or leukemia morphologically and remain stable hematologically. It is of interest to note that in a separate study of 11 patients with MDS from this laboratory, all were shown to have hematopoietic cell defects with normal functioning stroma using the same experimental conditions in LTBMC." It is tempting to speculate that the residual hematopoietic defect seen in all patients in this study following immunosuppressive therapy may predispose to the later development of clonal disorders such as MDS, AML, and PNH. Furthermore, it is likely that immunosuppressive therapy does not cure the underlying disorder, but may modify it sufficiently to allow some degree of recovery of marrow function. Whether treatment itself with ALG plays a role in progression to clonal disease or whether it merely allows patients to survive long enough to develop such a clonal disorder that would have arisen as part of the natural history of the aplasia is not clear. Regular long-term follow-up of patients with AA treated with immunosuppressive therapy is essential in order to detect early hematologic and/or cytogenetic evidence of these complications.
